ANAGENICS LIMITED — AGM Information 2016

Nov 20, 2016

==> picture [171 x 45] intentionally omitted <==

ASX ANNOUNCEMENT

AGM PRESENTATION

SYDNEY, Monday 21 November 2016: Cellmid Limited (ASX:CDY) provides the following presentation for the Annual General Meeting of the shareholders.

End Contact: Maria Halasz, CEO T +612 9221 6830 @mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lyramid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally. Intellectual property pertaining to midkine is being exploited through wholly owned subsidiaries Lyramid and Kinera. Advangen, Cellmid’s consumer health business, sells its FGF5 inhibitor hair growth products in Australia and Japan, and currently expanding distribution in other territories. For further information, please see www.cellmid.com.au, www.evolisproducts.com.au and www.evolisprofessional.com.

Advangen Limited and hair growth products

Advangen Limited is Cellmid’s wholly owned subsidiary engaged in the development and sale of anti-aging hair care products. Advangen has a range of FGF5 inhibitor hair growth products which are sold in Australia and Japan with a USA launch currently ongoing. Advangen has a rich portfolio of hair growth and anti-aging hair care assets which include formulations of products on market, trademarks, patents and patent applications, proprietary assays and manufacturing processes.

Investment in life sciences companies

There are a number of inherent risks associated with the research, development and commercialisation of pharmaceutical products. Investment in companies specialising in these activities carry specific risks which are different to those associated with trading and manufacturing businesses. As such, these companies should be regarded as highly speculative. Cellmid recommends that investors seek professional advice before making an investment in its shares.

CELLMID LIMITED ACN 111 304 119 ASX I CDY Suite 1802, Level 18, 15 Castlereagh Street, Sydney NSW 2000 AUSTRALIA TELEPHONE +61 2 9221 6830 FACSIMILE +61 2 9221 8535 WEB www.cellmid.com.au

==> picture [176 x 140] intentionally omitted <==

==> picture [43 x 93] intentionally omitted <==

==> picture [37 x 73] intentionally omitted <==

==> picture [34 x 86] intentionally omitted <==

==> picture [88 x 98] intentionally omitted <==

==> picture [41 x 94] intentionally omitted <==

==> picture [34 x 68] intentionally omitted <==

==> picture [38 x 87] intentionally omitted <==

==> picture [87 x 99] intentionally omitted <==

==> picture [44 x 93] intentionally omitted <==

==> picture [37 x 73] intentionally omitted <==

==> picture [35 x 86] intentionally omitted <==

==> picture [89 x 98] intentionally omitted <==

CELLMID LIMITED ANNUAL GENERAL MEETING

21 November 2016

Maria Halasz

CEO & Managing Director halasz@cellmid.com.au

==> picture [30 x 25] intentionally omitted <==

@mariahalasz

==> picture [960 x 84] intentionally omitted <==

----- Start of picture text -----

IMPORTANT NOTICE
----- End of picture text -----

Summary information

This presentation contains summary information about Cellmid Limited (Cellmid) and its activities as at November 2016. The information in this presentation is of a general nature and does not purport to be complete or contain all information that a prospective investor should consider when evaluating an investment decision in Cellmid or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations Act 2001 (Cth) (Corporations Act). This Presentation should be read in conjunction with Cellmid’s other periodic news releases or ASX disclosure documents as available from time to time.

Forward looking statements

This Presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this presentation. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of advertising and sales activities and competition.

2

==> picture [196 x 43] intentionally omitted <==

==> picture [960 x 85] intentionally omitted <==

----- Start of picture text -----

CELLMID (CDY:ASX)
----- End of picture text -----

Fully Paid Ordinary Shares (1 August 2016) Market Capitalisation (18 November 2016)

Fully Paid Ordinary Shares (1 August 2016) 1,063,867,011 Market Capitalisation (18 November 2016) A$32 million 38,440,000 Unlisted options Cash Position ( reported 30 September plus Placement) A$4.6 million Debt ($700K due Feb 2017, secured against R&D Tax Credit) A$1.2 million

3

==> picture [196 x 43] intentionally omitted <==

==> picture [960 x 85] intentionally omitted <==

----- Start of picture text -----

CELLMID (CDY:ASX)
----- End of picture text -----

• Cellmid is an Australian life sciences company listed on the ASX (CDY:ASX)

• Cellmid has three wholly owned subsidiaries with dedicated therapeutic targets:

• Lyramid (chronic kidney disease, bone disorders and cancer including cancer diagnostic)

• Kinera (heart failure)

• Advangen (hair loss)

• Cellmid is a revenue stage company with a rapidly growing consumer health business and a high value drug pipeline

4

==> picture [196 x 43] intentionally omitted <==

==> picture [960 x 85] intentionally omitted <==

----- Start of picture text -----

CELLMID: CORPORATE AND BUSINESS STRUCTURE
----- End of picture text -----

Cellmid Limited Lyramid Limited Kinera Limited CAB102 CMK103 Chronic kidney disease Heart failure Bone disorders Chronic heart conditions Brain tumour

Advangen Limited èvolis® Hair growth products OTC

5

==> picture [196 x 43] intentionally omitted <==

==> picture [960 x 85] intentionally omitted <==

----- Start of picture text -----

2016 SHARE PRICE PERFORMANCE
----- End of picture text -----

==> picture [807 x 261] intentionally omitted <==

----- Start of picture text -----

B5
B2 B4 0.040
B3 B6
B1
A5
0.035
A4 0.030
A1
A2
A3
0.025
0.020
0.015
JAN 16 FEB 16 MAR 16 APR 16 MAY 16 JUN 16 JUL 16 AUG 16 SEP 16 OCT 16 NOV 16
----- End of picture text -----

==> picture [245 x 8] intentionally omitted <==

----- Start of picture text -----

JAN 16 FEB 16 MAR 16 APR 16
----- End of picture text -----

		B1	B1	Midkine interviews with PharmaTelevision published (29th Jun)
A1	Appointment of Elizabeth Masamune (4th Feb)
A2	Cellmid Investor Briefing Call (25th Feb)		B2	USA Distribution Partnershipfor Cellmid's évolis®(20th Jul)
A3	Midkine Strategy Update (8th Apr)		B3	Newpublication for Cellmid's Midkine antibody (9th Aug)
A4	Record monthly sales for Advangen Japan (26th May)		B4	Cellmid's MK Antibodies Show Anti-tumor ActivityAgainst Brain Cancer(5th Oct)
A5	évolis®Professional Launch (14th Jun)		B5	Cellmid Records Highest EverQuarterlySales For évolis®(10th Oct)
		B6		USA launch of évolis®(3rd Nov)

6

==> picture [196 x 43] intentionally omitted <==

==> picture [960 x 85] intentionally omitted <==

----- Start of picture text -----

BOARD MEMBERS
----- End of picture text -----

==> picture [98 x 99] intentionally omitted <==

Dr David King | Chairman

An experienced independent chairman with expertise in high growth companies, Dr King has a track record in building business ventures and developing them into attractive takeover targets.

==> picture [107 x 104] intentionally omitted <==

Bruce Gordon | Non-Executive Director

Bruce is a seasoned audit partner and corporate finance specialist with over 35 years’ industry experience. Bruce brings significant expertise in valuations, mergers and acquisitions, restructuring and transaction support.

==> picture [89 x 96] intentionally omitted <==

Maria Halasz| CEO and Managing Director

With over 23 years in the life sciences sector Maria started in corporate finance before joining Cellmid nine years ago as CEO. Maria led the acquisition of the company’s current portfolio of midkine and FGF5 inhibitor assets.

==> picture [108 x 107] intentionally omitted <==

Dr Fintan Walton | Non-Executive Director

Dr Walton has over 33 years experience in the global pharmaceutical and biotechnology sector and is the Founder and CEO of PharmaVentures Ltd, a UK based corporate advisory firm.

7

==> picture [196 x 43] intentionally omitted <==

==> picture [960 x 85] intentionally omitted <==

----- Start of picture text -----

FY2016 HIGHLIGHTS
----- End of picture text -----

• April 2016: Strategic repositioning of Lyramid and Kinera (midkine pipeline companies) • April 2016: Fourth Midkine Symposium: new partnerships to enhance MK pipeline • May 2016: Record monthly sales for Advangen Japan ($575K in April 2016) • June 2016: Launching the évolis® Professional salon range in Australia • June 2016: New publication on Cellmid’s antibodies in bone healing • July 2016: USA distribution partnership for the évolis® hair loss products • Oct 2016: Anti-tumour activity for MK antibodies in brain cancer • Oct 2016: Highest ever quarterly revenue: over $1 million for the first time

8

==> picture [196 x 43] intentionally omitted <==

==> picture [960 x 85] intentionally omitted <==

----- Start of picture text -----

ÉVOLIS® AUSTRALIAN PHARMACY RANGE
----- End of picture text -----

==> picture [67 x 153] intentionally omitted <==

==> picture [70 x 153] intentionally omitted <==

==> picture [102 x 235] intentionally omitted <==

==> picture [94 x 238] intentionally omitted <==

==> picture [222 x 255] intentionally omitted <==

==> picture [236 x 263] intentionally omitted <==

Men’s Women’s Men’s Women’s Men’s Women’s Tonic Tonic Shampoo Shampoo Active Pack Active Pack

9

==> picture [196 x 43] intentionally omitted <==

==> picture [960 x 85] intentionally omitted <==

----- Start of picture text -----

ÉVOLIS® AUSTRALIAN SALON RANGE
----- End of picture text -----

==> picture [293 x 209] intentionally omitted <==

==> picture [302 x 216] intentionally omitted <==

Youth

for youthful age defying hair

Boost for stronger, thicker, healthier hair

Life

for superior hydration and damage repair

Vivid for colour treated hair

10

==> picture [196 x 43] intentionally omitted <==

==> picture [960 x 85] intentionally omitted <==

----- Start of picture text -----

ADVANGEN JAPANESE RANGE
----- End of picture text -----

==> picture [107 x 301] intentionally omitted <==

==> picture [119 x 283] intentionally omitted <==

==> picture [92 x 284] intentionally omitted <==

==> picture [129 x 289] intentionally omitted <==

Jo-Ju scalp lotion for women

Jo-Ju shampoo for women

Lexilis scalp Lexilis shampoo lotion for men for men

11

==> picture [196 x 43] intentionally omitted <==

==> picture [960 x 85] intentionally omitted <==

----- Start of picture text -----

ÉVOLIS® USA RANGE
----- End of picture text -----

==> picture [671 x 388] intentionally omitted <==

12

==> picture [196 x 43] intentionally omitted <==

==> picture [960 x 85] intentionally omitted <==

----- Start of picture text -----

THE PROBLEM
----- End of picture text -----

==> picture [653 x 381] intentionally omitted <==

13

==> picture [196 x 43] intentionally omitted <==

==> picture [960 x 85] intentionally omitted <==

----- Start of picture text -----

THE PROBLEM
----- End of picture text -----

Play Video

14

==> picture [960 x 85] intentionally omitted <==

----- Start of picture text -----

THE PROBLEM IS REAL
----- End of picture text -----

80 million 60% 47%

==> picture [188 x 16] intentionally omitted <==

==> picture [191 x 16] intentionally omitted <==

==> picture [103 x 16] intentionally omitted <==

==> picture [377 x 219] intentionally omitted <==

==> picture [287 x 23] intentionally omitted <==

==> picture [194 x 22] intentionally omitted <==

COPYRIGHT © BY ADVANGEN/ ALL RIGHTS RESERVED

==> picture [960 x 85] intentionally omitted <==

----- Start of picture text -----

THE OPTIONS
----- End of picture text -----

Topical

Medicinal

Surgical

==> picture [172 x 16] intentionally omitted <==

==> picture [138 x 15] intentionally omitted <==

==> picture [134 x 16] intentionally omitted <==

==> picture [185 x 16] intentionally omitted <==

==> picture [194 x 16] intentionally omitted <==

==> picture [73 x 16] intentionally omitted <==

==> picture [188 x 16] intentionally omitted <==

==> picture [117 x 16] intentionally omitted <==

==> picture [187 x 16] intentionally omitted <==

==> picture [192 x 16] intentionally omitted <==

==> picture [85 x 15] intentionally omitted <==

==> picture [175 x 16] intentionally omitted <==

==> picture [165 x 16] intentionally omitted <==

==> picture [200 x 16] intentionally omitted <==

==> picture [186 x 16] intentionally omitted <==

==> picture [156 x 16] intentionally omitted <==

==> picture [199 x 16] intentionally omitted <==

==> picture [142 x 16] intentionally omitted <==

==> picture [173 x 16] intentionally omitted <==

==> picture [85 x 16] intentionally omitted <==

==> picture [183 x 16] intentionally omitted <==

==> picture [127 x 16] intentionally omitted <==

==> picture [197 x 16] intentionally omitted <==

==> picture [55 x 16] intentionally omitted <==

==> picture [176 x 16] intentionally omitted <==

==> picture [114 x 16] intentionally omitted <==

==> picture [161 x 16] intentionally omitted <==

==> picture [182 x 16] intentionally omitted <==

==> picture [165 x 16] intentionally omitted <==

==> picture [155 x 16] intentionally omitted <==

==> picture [164 x 16] intentionally omitted <==

==> picture [54 x 16] intentionally omitted <==

==> picture [83 x 16] intentionally omitted <==

COPYRIGHT © BY ADVANGEN/ ALL RIGHTS RESERVED

==> picture [196 x 43] intentionally omitted <==

==> picture [960 x 85] intentionally omitted <==

----- Start of picture text -----

THE ALTERNATIVE
----- End of picture text -----

A NATURAL ALTERNATIVE TO COMBAT HAIR LOSS

17

COPYRIGHT © BY ADVANGEN/ ALL RIGHTS RESERVED

THE INGREDIENTS

==> picture [675 x 393] intentionally omitted <==

COPYRIGHT © BY ADVANGEN/ ALL RIGHTS RESERVED

==> picture [196 x 43] intentionally omitted <==

==> picture [960 x 85] intentionally omitted <==

----- Start of picture text -----

THE BELIEVERS
----- End of picture text -----

==> picture [655 x 380] intentionally omitted <==

20

==> picture [196 x 43] intentionally omitted <==

==> picture [960 x 85] intentionally omitted <==

----- Start of picture text -----

THE BELIEVERS
----- End of picture text -----

==> picture [681 x 384] intentionally omitted <==

Play Video

21

==> picture [196 x 43] intentionally omitted <==

==> picture [960 x 85] intentionally omitted <==

----- Start of picture text -----

AUSTRALIAN MARKET STRATEGY
----- End of picture text -----

• Continue to grow the national pharmacy and salon distribution for évolis®

• Currently ranging secured in 1,612 pharmacies, improve ranging

• Build the national distribution to 400 salons by June 2017

• Increase market penetration in all retail channels by

• Strong representation in pharmacies by our dedicated team

• TV advertising

• Increase direct to consumer sales by

• Social and digital campaigns

• PR focused on bloggers and influencers

22

==> picture [196 x 43] intentionally omitted <==

==> picture [960 x 85] intentionally omitted <==

----- Start of picture text -----

KEY OBJECTIVES – CONSUMER HEALTH
----- End of picture text -----

1. USA: Direct to consumer sales, retail and salon distribution

• Grow direct customer base to 10,000 by June 2017

• Retail launch in mid-2017

• Targeting $100 million in revenue in 7 years

2. Japan: Increase sales and profitability

• Continue to grow sales through QVC, salons and private label with improved profitability

• Open évolis® concept store in Tokyo

3. Australia and other regions: open channels in China, Europe and SE Asia

• Increase sell through in Australian pharmacy and broaden salon distribution

• Continue business development; China through e-commerce and other markets through retail

23

==> picture [196 x 43] intentionally omitted <==

==> picture [960 x 85] intentionally omitted <==

----- Start of picture text -----

KEY OBJECTIVES – LYRAMID AND KINERA
----- End of picture text -----

1. Build key opinion leader network for Lyramid and Kinera

2. Build on existing academic and commercial collaborations

3. Fund subsidiary companies directly

• avoid dilution in Cellmid; and

• add valuation upside

4. Complete preclinical development and commence clinical development for Kinera

5. Complete preclinical development and finalise clinical indication for Lyramid

24

==> picture [196 x 43] intentionally omitted <==

==> picture [960 x 85] intentionally omitted <==

----- Start of picture text -----

FINANCIAL PERFORMANCE
----- End of picture text -----

Results (AU$)		2014	2015	2016
Total revenue		1,898,037	2,930,518	4,571,599	141%
Sales Revenue		1,150,931	1,842,804	3,120,367	171%
Midkine revenue		1,009,188	99,263	205,390
R&D tax credit/grants		747,106	988,451	1,121,562
Total expenditure		5,023,890	6,301,547	8,098,979	61%
R&D spending		1,660,236	2,196,558	2,492,360	50%
Current assets		4,499,891	4,173,616	5,131,104	14%
Revenue/Expenditure*		38%*	47%	56%

• Not including one off license fee

25

==> picture [196 x 43] intentionally omitted <==

==> picture [956 x 85] intentionally omitted <==

----- Start of picture text -----

SUMMARY
----- End of picture text -----

• Cellmid has a balanced portfolio of life sciences assets with strong global revenue growth expected from consumer health

• Major potential upside from midkine drug therapeutics (partnerships and licenses)

• Track record of delivering sales growth year on year, with sales up 72% in FY2016

• Experienced management team and strong partners to deliver on growth prospects

26

==> picture [196 x 43] intentionally omitted <==

==> picture [960 x 86] intentionally omitted <==

----- Start of picture text -----

THANK YOU
----- End of picture text -----

Cellmid Limited

==> picture [31 x 30] intentionally omitted <==

15 Castlereagh Street Sydney NSW 2000 AUSTRALIA T: +61 2 9221 6830 F: +61 2 9233 8975 www.cellmid.com.au www.evolisproducts.com.au www.evolisprofessional.com.au